文献速递慢性肾脏病肾移植肾血管病与高血压

循环PCSK9水平与严重慢性肾脏病患者预后的关联

Association between circulating proprotein convertase subtilisin/kexin type 9 levels and prognosis in patients with severe chronic kidney disease.
PubMed 文献 · Nephrol Dial Transplant · 2020-01-01

在167例肾移植候选者中比较PCSK9水平与健康对照,并分析其与LDL-c、冠状动脉病变及MACE和死亡的关系。结果显示PCSK9水平与健康对照无差异,未接受降脂治疗者PCSK9与LDL-c正相关,但PCSK9与阻塞性CAD、LDL-c(多回归)、冠状动脉钙化评分及随访3.7年的MACE或死亡均无关联。

要点

  • 肾移植候选者PCSK9水平与健康对照无显著差异。
  • 未降脂治疗者PCSK9与LDL-c正相关(rho=0.24,P<0.05)。
  • PCSK9未能预测该人群MACE或死亡。

核心结论

  • PCSK9水平预测心血管疾病和预后的能力似乎不适用于肾移植候选者队列。

研究设计与样本

  • 研究纳入167例肾移植候选者,移植前接受冠状动脉CT血管造影和侵入性冠状动脉造影,另设79例健康对照。
  • MACE和死亡数据来自Western Denmark Heart Registry、病历回顾和患者访谈,随访3.7年。

主要发现

  • 健康对照与肾移植候选者的平均PCSK9水平无差异。
  • 未接受降脂治疗的患者中,PCSK9与LDL-c正相关(rho=0.24,P<0.05)。
  • 在CCTA和ICA上,有无阻塞性CAD患者的平均PCSK9相似。
  • 多回归分析中,PCSK9与LDL-c(β=-6.45,P=0.44)及冠状动脉钙化评分(β=2.17,P=0.84)均无关联。
  • 随访3.7年期间,PCSK9水平与MACE或死亡均无关联。

临床怎么用

  • 在肾移植候选者中,PCSK9水平不宜作为心血管风险或预后的独立预测指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic kidney disease is a risk factor for premature development of coronary atherosclerosis and mortality. A high level of proprotein convertase subtilisin/kexin type 9 (PCSK9) is a recently recognized cardiovascular risk factor and has become the target of effective inhibitory treatment. In 167 kidney transplantation candidates, we aimed to: (i) compare levels of PCSK9 with those of healthy controls, (ii) examine the association between levels of PCSK9 and low-density lipoprotein cholesterol (LDL-c) and the degree of coronary artery disease (CAD) and (iii) evaluate if levels of PCSK9 predict major adverse cardiac events (MACE) and mortality. METHODS: Kidney transplant candidates (n = 167) underwent coronary computed tomography angiography (CCTA) and invasive coronary angiography (ICA) before transplantation. MACE and mortality data were extracted from the Western Denmark Heart Registry, a review of patient records and patient interviews. A group of 79 healthy subjects were used as controls. RESULTS: Mean PCSK9 levels did not differ between healthy controls and kidney transplant candidates. In patients not receiving lipid-lowering therapy, PCSK9 correlated positively with LDL-c (rho = 0.24, P < 0.05). Mean PCSK9 was similar in patients with and without obstructive CAD at both CCTA and ICA. In a multiple regression analysis, PCSK9 was associated with neither LDL-c (β=-6.45, P = 0.44) nor coronary artery calcium score (β=2.17, P = 0.84). During a follow-up of 3.7 years, PCSK9 levels were not associated with either MACE or mortality. CONCLUSIONS: The ability of PCSK9 levels to predict cardiovascular disease and prognosis does not seem to apply to a cohort of kidney transplant candidates.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Rasmussen LD, Bøttcher M, Ivarsen P, et al. Association between circulating proprotein convertase subtilisin/kexin type 9 levels and prognosis in patients with severe chronic kidney disease. Nephrol Dial Transplant. 2020. PMID: 30137516. doi:10.1093/ndt/gfy257

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。